|
|
||||||||
Intensive Care Unit, Children's Cardiac Center, Bratislava, Slovakia
Accepted for publication April 24, 2009.
* Address correspondence to Dr Kovacikova, Children's Cardiac Center, Limbova 1, Bratislava, 833 51, Slovakia (Email: lkovacikova{at}yahoo.com).
| Abstract |
|---|
|
|
|---|
Methods: The study included 40 pediatric cardiosurgical patients with postoperative junctional ectopic tachycardia. Intravenous amiodarone in 2-mg/kg boluses and, if necessary, as continuous infusion (10 to 15 µg/kg/min), were used as the first-line therapy. Restoration of sinus rhythm or slowing of junctional ectopic tachycardia to a rate that allowed atrial or atrioventricular sequential pacing was considered as efficacy of therapy.
Results: Amiodarone was effective in 18 patients (45%). Sinus rhythm was achieved in 7, and heart rate decreased in 11 patients from 180 (range, 173 to 200) to 142 (range, 133–155) beats/min (p < 0.0001) and allowed effective pacing with atrioventricular synchrony. Higher arteriovenous oxygen saturation difference (p = 0.007) and lower body temperature (p = 0.02) were associated with failure of amiodarone therapy.
Conclusions: Amiodarone as the first-line treatment was effective in almost half of the patients with postoperative junctional ectopic tachycardia. Higher arteriovenous oxygen saturation difference and lower body temperature were associated with failure of amiodarone therapy, and their presence may suggest more aggressive initial approach consisting of amiodarone combined with hypothermia.
| Introduction |
|---|
|
|
|---|
Pharmacologic interventions such as digoxin, intravenous procainamide, flecainide, and propranolol have been used in management of JET with varying degrees of success [1–4, 9–12]. The most encouraging results have been reported with intravenous amiodarone, and therefore, amiodarone was suggested as the possible first-line therapy of postoperative JET [13–17]. Data regarding its efficacy and safety are limited, however.
Since 1998 our treatment protocol for JET has consisted of intravenous amiodarone as the first-line therapy and induced hypothermia as the second-line therapy if amiodarone failed to treat JET. The primary hypothesis of this study was that amiodarone as a first-line pharmacologic therapy leads to restoration of sinus rhythm or significant slowing of the heart rate. The secondary hypothesis was that certain perioperative factors are predictive for failure of amiodarone therapy.
| Patients and Methods |
|---|
|
|
|---|
Diagnosis of JET
Diagnosis of JET was made from the surface and atrial electrocardiogram (Cardiovit AT-5, Schiller, Switzerland). JET was characterized by (1) tachycardia with a heart rate faster than 170 bpm, usually exhibiting a pattern of "warm up" at initiation, (2) a narrow QRS or wide QRS in the presence of surgically induced bundle branch block, and (3) the presence of atrioventricular dissociation with a ventricular rate greater than the atrial rate or retrograde 1:1 ventriculoatrial conduction.
Therapy Protocol for JET
First-line therapy with amiodarone and second-line therapy with hypothermia was used as described below:
First-line therapy with amiodarone
Amiodarone was administered according to protocol, where 2-mg/kg intravenous boluses were given over a 5 to 10 minutes, with a maximum total initial bolus dose of 10 mg/kg. After boluses, a continuous infusion of 10 to 15 µg/kg/min was used, if necessary, with the dose and duration of infusion therapy at the discretion of the treating physician. If JET responded initially to amiodarone boluses, but later recurred, an additional 2-mg/kg dose was administered; however, the total daily bolus dose of amiodarone could not exceed 15 mg/kg.
The efficacy of amiodarone therapy was defined as the restoration of sinus rhythm or the slowing of junctional rhythm to an acceptable heart rate that allowed hemodynamic improvement with atrial or atrioventricular sequential pacing. Failure of amiodarone therapy was defined as persistently rapid JET or late increases in the JET rate exceeding 170 bpm requiring escalation of therapy to hypothermia. Safety of amiodarone therapy was defined as absence of hemodynamic instability requiring intervention.
Second-line therapy with hypothermia
Core temperature was reduced to 31° to 35°C by using cooling blankets and insulated ice packs placed around the head and trunk. The patients were sedated, mechanically ventilated, and paralyzed to prevent shivering. The temperature was continuously monitored through a rectal thermistor.
Data Collection
Demographic, surgical, and hemodynamic data, and details related to JET and amiodarone therapy were collected longitudinally by completing forms developed for the study.
Heart rhythm and rate, elapsed time from admission from the operating room until the JET occurrence, and type of atrioventricular conduction were assessed from records of continuous electrocardiographic (ECG) monitoring. The dose of amiodarone and the overall duration of continuous infusion of amiodarone therapy necessary for effective treatment of JET were calculated. Data on heart rate and arterial blood pressure were obtained at baseline and at 1, 2, 3, 6, and 12 hours after the initiation of treatment with amiodarone as well as the arteriovenous (AV) oxygen saturation difference at baseline and at 6 and 12 hours after the initiation of treatment with amiodarone. The number of patients with successful amiodarone therapy was assessed. Predictors of failure of amiodarone therapy were defined. Data on the duration and depth of hypothermia was assessed.
Statistical Analysis
Continuous data are presented as median and range. The t test was used for comparison of variables between the patients treated with amiodarone only and those who required hypothermia added to amiodarone therapy. A paired t test was used for time analysis of heart rate, blood pressure, and AV oxygen saturation difference. Univariate analysis (logistic regression and
2 test) was used to assess the factors associated with the need of escalation therapy to hypothermia. Significant risk factors were entered into a multivariate analysis using a forward stepwise logistic regression model to determine optimal coefficient of determination (R
2). Analysis was done with JMP 5.0.1a software (SAS Institute Inc, Cary, NC), and p < 0.05 was considered significant.
| Results |
|---|
|
|
|---|
|
2.5) in 4 (10%). Median peak junctional rates were 187 bpm (range, 170 to 230 bpm). There was no difference in JET rate between neonates and older patients.
Amiodarone Efficacy
Treatment with amiodarone was effective in 18 patients (45%). Boluses of amiodarone with median dose of 3 mg/kg (range, 2 to 10 mg/kg) were effective in restoring sinus rhythm in 7 patients. In the remaining 11 patients, junctional rhythm persisted after amiodarone boluses of 8 mg/kg (range, 4 to 10 mg/kg) and continuous infusion of amiodarone with duration of 23 hours (range, 8 to 55 hours). However; the rate decreased from 180 bpm (range, 173 to 200 bpm) to 142 bpm (range, 133 to 155 bpm; p < 0.0001) and allowed effective pacing with atrioventricular synchrony.
The treatment with amiodarone alone was not sufficient in 22 patients (55%), and escalation to hypothermia was required. In these patients, initial amiodarone boluses at the dose of 10 mg/kg (range, 4 to 10 mg/kg) decreased the JET rate from 190 bpm (range, 170 to 230 bpm) to 162 bpm (range, 155 to 210 bpm; (p = 0.02). The heart rate in 8 patients did not decrease adequately to allow atrial pacing, and therapy with hypothermia was initiated. The rate decrease in 14 patients was sufficient to allow pacing; however, late increases in the JET rate exceeding 170 bpm required escalation of therapy. The patients were cooled to a median temperature of 33°C (range, 31° to 35°C). Cooling was maintained for a median of 34 hours (range, 14 to 168 hours). In 20 of 22 patients, a continuous amiodarone infusion for a median duration of 50 hours (range, 12 to 132 hours) was also used to control heart rate.
Hemodynamic Data
In patients who responded to amiodarone, the heart rate decreased during the first hour after initiation of treatment from 180 bpm (range, 170 to 200 bpm) to 156 bpm (range, 105 to 176 bpm; p < 0.0001). During the next hour, heart rate further decreased (p = 0.01) and did not change significantly afterwards. In the patients who required treatment with amiodarone and hypothermia, the heart rate decreased during the first hour after initiation of treatment from 190 bpm (range, 170 to 230 bpm) to 169 bpm (129 to 214 bpm) (p < 0.0001) and did not change significantly afterwards (Fig 1). At all time points after the initiation of treatment, the heart rate was higher in patients who required hypothermia than in patients who responded to therapy with amiodarone (Table 2).
|
|
AV oxygen saturation difference did not change at measurement times (Fig 1) in either group. AV was significantly higher in patients who required therapy with hypothermia compared with the patients who responded to amiodarone alone (Table 2).
No deaths occurred in association with JET. In the patients who responded to amiodarone alone, permanent sinus rhythm occurred 24 hours (range 0.5 to 72 hours) after the initiation of the therapy compared with 42 hours (range, 4 to 264 hours; p = 0.035) in the patients who required hypothermia.
Amiodarone Safety
During administration of amiodarone boluses, hypotension occurred in 28 patients, with good response to calcium or volume expansion in 23 and with a need to increase catecholamine support in 5 patients. One patient required cardiopulmonary resuscitation, including cardiac massage. No proarrhythmic effects of amiodarone, atrioventricular block, or bradycardia were documented.
Predictors of Failure
Predictors of amiodarone therapy failure are summarized in Table 3. By univariate analysis, patients who needed escalation therapy to hypothermia were younger, had lower body weight, early onset of JET, lower body temperature, and higher AV oxygen saturation difference. Also, there was an association between the need for hypothermia and repair of total anomalous pulmonary venous drainage.
|
| Comment |
|---|
|
|
|---|
Even though the study was not designed to identify risk factors associated with postoperative JET, it seems that its occurrence was related mostly to operations with an increased risk of direct trauma to the conduction system, such as tetralogy of Fallot and ventricular septal defect repair. This is in accordance with findings of previous investigators [11, 25]. In our study, JET occurred rarely in surgical repairs such as the Fontan procedure and the arterial switch operation, which were showed to be associated with JET occurrence [11, 15].
At our institution, atrial pacing wires are routinely placed after operations for congenital heart disease. The wires are used for pacing immediately when accelerated junctional rhythm occurs. We may speculate that optimizing an atrioventricular synchrony may prevent a progression to JET in some patients.
Dorman and colleagues [26] suggest that magnesium depletion in the postoperative setting may significantly increase the risk that JET will develop. Our institution uses an aggressive protocol to detect and correct electrolyte and acid-base abnormalities. Magnesium sulphate is administered in the operating room and the intensive care unit immediately after any rhythm disturbance occurs, even if it is subtle. As a standard care, a bolus of magnesium sulfate (50 mg/kg) is administered into the bypass circuit after aortic unclamping in all patients.
Efficacy of Amiodarone
The main finding of the study is that amiodarone alone was sufficient in 45% of patients with postoperative JET. Hypothermia was needed as the second-line treatment in the remaining 55%.
Several authors have studied the efficacy and safety of amiodarone in the management of postoperative arrhythmias [3, 13–16, 27–29]. Perry and colleagues [27] reported success in 13 of the 14 patients who received intravenous amiodarone for postoperative JET. A beneficial effect was noted during the initial amiodarone bolus (mean load, 6.3 mg/kg) where 5 patients converted to sinus rhythm and 8 slowed to the rate allowing atrial or atrioventricular sequential pacing. Raja and colleagues [16] reported the use of amiodarone as a bolus of 5 mg/kg and subsequent infusion to control JET. The JET rate reduced to less than 180 bpm within 2 hours in 10 of 16 patients.
Saul and colleagues [28] conducted double-blind, randomized, dose-response study on the safety and efficacy of intravenous amiodarone for treatment of incessant tachyarrhythmias, including 28 patients with postoperative JET. Drug loading dosages were 1, 5 and 10 mg/kg during the first hour, plus a daily maintenance of 1, 5, and 10 mg/kg during the next 48 hours for low-, medium-, and high-dose groups, respectively. Success was achieved in 11.1%, 20.0%, and 33.3%, respectively, at the end of the loading dose and in 66.7%, 70.0%, and 83.3% at the end of the 48-hour treatment phase.
The methodology in each of these studies varied significantly. Differences were related to size and duration of a loading dose and to the study population that may have included patients with arrhythmia refractory to first-line therapy with hypothermia or pharmacologic agents, or both. Also, the definitions of successful therapy were not standardized.
Predictors for Amiodarone Failure
Although univariate analysis showed multiple factors such as young age, low body weight, early onset of JET, low body temperature, high AV oxygen saturation difference, and total anomalous pulmonary venous drainage repair were associated with the need for hypothermia, the multivariate analysis showed only low body temperature and higher AV oxygen saturation difference were associated with the need for hypothermia. This is partly explained by the interdependence of these factors, in that smaller patient size is associated with enhanced difficulty in surgical access. Interdependence of early onset of JET and lower body temperature may be clarified by the tight body temperature control that is applied very early in the operating room when JET is suspected.
We found a high AV oxygen saturation difference, a measure of low cardiac output state, was an independent and significant risk factor for the need of escalation therapy to hypothermia. This finding suggests that irrespective of heart rate, JET may be more resistant to amiodarone when a profound decrease in cardiac output accompanies tachycardia. An important question raised by many authors of previous reports is whether aggressive therapy is always indicated for JET. To quantify the hemodynamic effects of JET and the benefits of therapy is difficult [11]. However, several studies observed a trend toward lower arterial blood pressure and higher atrial pressures when rapid JET began [5, 6, 11, 16, 30, 31]. We detected an increase of blood pressure after initiation of treatment. Many centers suggest treatment of patients with JET rates of more than 170 bpm. Our results address that question because they show that the AV oxygen saturation difference might be better measure of the necessity for early treatment than JET rate alone.
The AV oxygen saturation difference was significantly higher in patients who required hypothermia therapy compared with patients who responded to amiodarone not only before therapy but also 6 and 12 hours after therapy was initiated. We may speculate that low cardiac output is a cause of JET that does not respond well to therapy; however, low cardiac output may be a result of such resistant JET.
Several studies have implicated the nature of the congenital heart disease and its repair as a major contributor to the genesis of JET [25, 31]. Our study demonstrates that surgical approaches may also influence responsiveness to therapeutic measures. An association between the need for hypothermia and total anomalous pulmonary venous drainage repair was observed. We speculate that this may be related to the age of our patients with total anomalous pulmonary venous drainage. All patients were neonates, and young age was a significant risk factor for the need of hypothermia. Furthermore, all patients had an infracardiac defect that requires a retraction of the heart out of the chest to allow dissection of the anomalous descending vertical vein.
The remaining three surgical subgroups were (1) perimembranous ventricular septal defect closure, (2) operations involving subarterial ventricular septal defect closure with right ventricular outflow tract resection in tetralogy of Fallot and its variants, and (3) the subgroup of remaining procedures. When these groups were compared, no association was found between operations and a need for hypothermia.
Cardiopulmonary bypass and aortic cross-clamp time, JET rate, and specific type of atrioventricular conduction did not have an influence on the responsiveness to amiodarone and the need for hypothermia in the management of JET.
Side Effects of Amiodarone
A low incidence of side effects was observed in previous retrospective studies [16, 17, 29]. However, the prospective study of Saul and colleagues [28] recorded a high rate of clinically significant adverse events, including hypotension, bradycardia, and atrioventricular block. Hypotension with subsequent intervention was common in our patients. This may be explained by a more rapid loading dose in our study compared with some previous studies and also because criteria for intervention were not strictly defined in neither our study nor in previous studies.
Study Strengths and Limitations
The strengths of this study are that it is prospective, single-institutional study marked by a consistency in two-staged treatment protocol throughout the study period and that it is a large reported patient group treated for JET with amiodarone as the only first-line treatment. An important question not addressed in this study is whether a different amiodarone treatment protocol would be more effective in the management of postoperative JET.
Recommendations and Conclusions
Amiodarone was effective in treatment of JET in 45% of patients. Use of amiodarone in these patients allowed avoidance of deep sedation, muscle paralysis, and possible adverse effects of hypothermia on hemodynamics and immune function. Amiodarone provided a return of sinus rhythm very shortly after initiation of therapy in some patients. In remaining 55% of patients, escalation of the therapy to hypothermia was required to facilitate slowing of JET to a rate at which atrial or atrioventricular sequential pacing was possible. The higher AV oxygenation saturation difference and low body temperature at the onset of JET were risk factors for a need of induced hypothermia as a second-line treatment.
This analysis suggests a more aggressive protocol consisting of bolus doses, followed immediately by a continuous infusion for 24 to 48 hours, might reduce the need for escalation therapy to hypothermia. Several authors have advocated such treatment [13, 16, 17], and we began applying this approach after we analyzed the data reported here. Alternatively, a more aggressive approach consisting of amiodarone combined with hypothermia as the first-line therapy may be more effective if the risk of amiodarone therapy failure is present.
| References |
|---|
|
|
|---|
Related Article
This article has been cited by other articles:
![]() |
L. Mildh, A. Hiippala, P. Rautiainen, V. Pettila, H. Sairanen, and J.-M. Happonen Junctional ectopic tachycardia after surgery for congenital heart disease: incidence, risk factors and outcome Eur J Cardiothorac Surg, January 1, 2011; 39(1): 75 - 80. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Cecchin Invited Commentary Ann. Thorac. Surg., August 1, 2009; 88(2): 622 - 623. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |